Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastric Emptying Clear all
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

NCT00612014
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

NCT00050882
View directory record Official record
Conditions
Gastroparesis
Interventions
GM-611
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
67
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 11:37 PM EDT
Recruiting No phase listed Observational

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

NCT05711758
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Metabolic Disease, Delayed Gastric Emptying Following Procedure
Interventions
PSAM Treatment Patients
Procedure
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 11:37 PM EDT
Recruiting Not applicable Interventional

High Resolution Gastric Mapping and Gastroduodenal Manometry

NCT06941545
View directory record Official record
Conditions
Dyspepsia
Interventions
Alimetry, tVNS, Gastroduodenal Manometry
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans

NCT00871325
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 4, 2026, 11:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume

NCT03741777
View directory record Official record
Conditions
Fasting, Gastric Emptying
Interventions
Clear oral fluid
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Feasibility of a Wireless Patch System (WPS) to Measure Gastrointestinal Motility and Gastric Emptying

NCT05555407
View directory record Official record
Conditions
Gastric Emptying
Interventions
Scintigraphic gastric emptying scan, Wireless patch system (WPS)
Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 4, 2026, 11:37 PM EDT
Terminated Not applicable Interventional

How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements

NCT04306445
View directory record Official record
Conditions
Obesity
Interventions
GF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
Device · Dietary Supplement · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 4, 2026, 11:37 PM EDT
Enrolling by invitation No phase listed Observational

Endoscopic Metabolic and Bariatric Therapies

NCT05725967
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity Associated Disorder, Bariatric Surgery Candidate, Fistula, Gastric, Roux-en-y Anastomosis Site, Ulcer, Gastric, Abdominal Pain, Abdominal Obesity, Complication of Surgical Procedure, Complication of Treatment, Complication,Postoperative, Weight Gain, Weight Loss, Leak, Anastomotic, Delayed Gastric Emptying Following Procedure
Interventions
Primary Obesity Endoscopic Procedures, Endoscopic Revision of Bariatric Surgical Procedures, Bariatric Surgery Procedures, Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction, Intragastric Balloon, Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal, Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy, Aspiration Therapy
Procedure · Device
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years to 80 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

NCT00845858
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus, Delayed Gastric Emptying
Interventions
metoclopramide, Placebo
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
65
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 4, 2026, 11:37 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

POCUS Analysis of the Gastric Emptying Time of Orange Juice With and Without Pulp

NCT04146233
View directory record Official record
Conditions
Preoperative Period, Anesthesia
Interventions
Point of care gastric ultrasound
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastroparesis

NCT01469286
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
TEA, Sham-TEA
Device
Lead sponsor
Transtimulation Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234
View directory record Official record
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2
Interventions
Tirzepatide, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 4, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.

NCT06038734
View directory record Official record
Conditions
Delayed Gastric Emptying, Gastroparesis
Interventions
gastric ultrasound
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Oxybutynin Topical Gel on Gastric Emptying

NCT00926926
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride Gel, Placebo Gel
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ABCA2 GIRMS Analytical Validation Clinical Performance Study

NCT04607304
View directory record Official record
Conditions
Gastroparesis
Interventions
ABCA2 GIRMS
Device
Lead sponsor
Cairn Diagnostics
Industry
Eligibility
18 Years to 85 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Slowly Digestible Carbohydrates and the Ileal Brake

NCT03630445
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Isomaltooligosaccharides (IMOs), Xtend® sucromalt, Combination of IMOs and Xtend® sucromalt, Raw corn starch, Maltodextrin
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex To IMprove Bowel Function

NCT04546672
View directory record Official record
Conditions
Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying

NCT01844622
View directory record Official record
Conditions
Digestive System Disease
Interventions
Domperidone
Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 4, 2026, 11:37 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity

NCT05713071
View directory record Official record
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 11:37 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 4, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 4, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

NCT00952991
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
LAF237 = vildagliptin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 4, 2026, 11:37 PM EDT